Antithymocyte globulin in allogeneic hematopoietic cell transplantation: Benefits and limitations

Taiga Nishihori, Zaid Al-Kadhimi, Mehdi Hamadani, Mohamed A. Kharfan-Dabaja

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Significant advances have been made in allogeneic hematopoietic cell transplantation by reducing toxicities and optimizing its efficacy. Antithymocyte globulin (ATG) is an important in vivo T-cell depletion strategy, which reduces the risk of graft-versus-host disease in HLA-matched or -mismatched donor allografting. ATG effectively targets alloreactive T cells at the expense of potentially increasing the risk of post-hematopoietic cell transplantation infections and delayed immune reconstitution. We summarize the targets, mechanisms, various preparations of ATG, the growing role of ATG in prevention of graft-versus-host disease in various transplant modalities as well as emerging data on pharmacokinetic modeling for individualized ATG dosing. Further research is needed to optimize the ATG administration while minimizing the toxicities.

Original languageEnglish (US)
Pages (from-to)435-447
Number of pages13
JournalImmunotherapy
Volume8
Issue number4
DOIs
StatePublished - Apr 2016

Fingerprint

Antilymphocyte Serum
Cell Transplantation
Graft vs Host Disease
T-Lymphocytes
Homologous Transplantation
Pharmacokinetics
Transplants
Infection
Research

Keywords

  • ATG
  • GVHD
  • T-cell depletion
  • pharmacokinetics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Antithymocyte globulin in allogeneic hematopoietic cell transplantation : Benefits and limitations. / Nishihori, Taiga; Al-Kadhimi, Zaid; Hamadani, Mehdi; Kharfan-Dabaja, Mohamed A.

In: Immunotherapy, Vol. 8, No. 4, 04.2016, p. 435-447.

Research output: Contribution to journalReview article

Nishihori, Taiga ; Al-Kadhimi, Zaid ; Hamadani, Mehdi ; Kharfan-Dabaja, Mohamed A. / Antithymocyte globulin in allogeneic hematopoietic cell transplantation : Benefits and limitations. In: Immunotherapy. 2016 ; Vol. 8, No. 4. pp. 435-447.
@article{0f6b2c8f7e304a7ebafbfae091230072,
title = "Antithymocyte globulin in allogeneic hematopoietic cell transplantation: Benefits and limitations",
abstract = "Significant advances have been made in allogeneic hematopoietic cell transplantation by reducing toxicities and optimizing its efficacy. Antithymocyte globulin (ATG) is an important in vivo T-cell depletion strategy, which reduces the risk of graft-versus-host disease in HLA-matched or -mismatched donor allografting. ATG effectively targets alloreactive T cells at the expense of potentially increasing the risk of post-hematopoietic cell transplantation infections and delayed immune reconstitution. We summarize the targets, mechanisms, various preparations of ATG, the growing role of ATG in prevention of graft-versus-host disease in various transplant modalities as well as emerging data on pharmacokinetic modeling for individualized ATG dosing. Further research is needed to optimize the ATG administration while minimizing the toxicities.",
keywords = "ATG, GVHD, T-cell depletion, pharmacokinetics",
author = "Taiga Nishihori and Zaid Al-Kadhimi and Mehdi Hamadani and Kharfan-Dabaja, {Mohamed A.}",
year = "2016",
month = "4",
doi = "10.2217/imt.15.128",
language = "English (US)",
volume = "8",
pages = "435--447",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Antithymocyte globulin in allogeneic hematopoietic cell transplantation

T2 - Benefits and limitations

AU - Nishihori, Taiga

AU - Al-Kadhimi, Zaid

AU - Hamadani, Mehdi

AU - Kharfan-Dabaja, Mohamed A.

PY - 2016/4

Y1 - 2016/4

N2 - Significant advances have been made in allogeneic hematopoietic cell transplantation by reducing toxicities and optimizing its efficacy. Antithymocyte globulin (ATG) is an important in vivo T-cell depletion strategy, which reduces the risk of graft-versus-host disease in HLA-matched or -mismatched donor allografting. ATG effectively targets alloreactive T cells at the expense of potentially increasing the risk of post-hematopoietic cell transplantation infections and delayed immune reconstitution. We summarize the targets, mechanisms, various preparations of ATG, the growing role of ATG in prevention of graft-versus-host disease in various transplant modalities as well as emerging data on pharmacokinetic modeling for individualized ATG dosing. Further research is needed to optimize the ATG administration while minimizing the toxicities.

AB - Significant advances have been made in allogeneic hematopoietic cell transplantation by reducing toxicities and optimizing its efficacy. Antithymocyte globulin (ATG) is an important in vivo T-cell depletion strategy, which reduces the risk of graft-versus-host disease in HLA-matched or -mismatched donor allografting. ATG effectively targets alloreactive T cells at the expense of potentially increasing the risk of post-hematopoietic cell transplantation infections and delayed immune reconstitution. We summarize the targets, mechanisms, various preparations of ATG, the growing role of ATG in prevention of graft-versus-host disease in various transplant modalities as well as emerging data on pharmacokinetic modeling for individualized ATG dosing. Further research is needed to optimize the ATG administration while minimizing the toxicities.

KW - ATG

KW - GVHD

KW - T-cell depletion

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84962605020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962605020&partnerID=8YFLogxK

U2 - 10.2217/imt.15.128

DO - 10.2217/imt.15.128

M3 - Review article

C2 - 26973125

AN - SCOPUS:84962605020

VL - 8

SP - 435

EP - 447

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 4

ER -